Acer Therapeutics Report issue

For profit Phase 2 Phase 3
Founded: Cambridge MA United States (2013)
Status: Acquired by Zevra Therapeutics (2023)

Organization Overview

First Clinical Trial
2022
NCT05325775
First Marketed Drug
2022
sodium phenylbutyrate (buphenyl)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ACER | Acer Therapeutics Inc.

Active Ingredients

Marketed Drugs (1)

sodium phenylbutyrate (buphenyl) (2022)

Drugs in Phase 3 Trials (1)

celiprolol (1 trial)

Drugs in Phase 2 Trials (4)

Key: Acer Therapeutics (2) Acquired (2)

imilecleucel-t (1 trial)

osanetant (1 trial)

sodium phenylbutyrate (buphenyl) (1 trial)

tovaxin (3 trials)

Indications

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 5